SCHEMBL811265

SCHEMBL811265

CC(C)(C)OC(=O)Nc1ccc(Sc2ccc(OCc3cnc(Cl)s3)cc2[N+](=O)[O-])cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.48
MAPT P10636 6/20 0.44
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
LMNA P02545 3/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
POLB P06746 2/20 0.39
GAA P10253 2/20 0.39
USP7 Q93009 3/20 0.39
USP47 Q96K76 3/20 0.39
RAB9A P51151 1/20 0.39
ATM Q13315 1/20 0.39
PLA2G4A P47712 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
ALDH1A1 P00352 2/20 0.37
RECQL P46063 1/20 0.36
PRMT1 Q99873 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810699 0.88 L3MBTL1 (0.51) L3MBTL1MAPTMEN1KMT2ALMNA
SCHEMBL810698 0.88 L3MBTL1 (0.51) L3MBTL1MAPTMEN1KMT2ALMNA
SCHEMBL810430 0.86 L3MBTL1 (0.52) L3MBTL1MAPTMEN1KMT2ALMNA
SCHEMBL810604 0.83 MAPT (0.50) L3MBTL1MAPTMEN1KMT2ALMNA
SCHEMBL810563 0.81 PDE7A (0.55) L3MBTL1MAPTMEN1KMT2ALMNA
SCHEMBL5069003 0.78 MAPT (0.45) L3MBTL1MAPTMEN1KMT2APKM
SCHEMBL811015 0.77 PIM1 (0.45) L3MBTL1MAPTMEN1KMT2ALMNA
SCHEMBL1478058 0.77 ALDH1A1 (0.53) L3MBTL1MAPTMEN1KMT2ALMNA
SCHEMBL13305747 0.76 MAPT (0.47) MAPTMEN1KMT2ALMNAGAA
SCHEMBL811427 0.74 HTT (0.48) MAPTMEN1KMT2APOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 L3MBTL1 2884/4885MAPT 1347/4885MEN1 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.